Quantcast

Latest Proleukin Stories

2014-05-31 08:21:17

Data Support Adoption of Stable Disease as Response Criterion, Raise Intriguing Hypotheses about Sequential Therapy and Utility of IL-2 as Salvage Option CHICAGO, May 31, 2014 /PRNewswire/ -- Prometheus Laboratories Inc. announced today that data from the PROCLAIM(SM) national patient registry retrospective cohort document an improvement in median overall survival (OS) in patients with metastatic melanoma who were treated with high-dose Proleukin(®) (aldesleukin) as compared to...

2014-05-30 08:25:14

Retrospective Analysis Demonstrates Survival Benefits for Patients with Stable and Progressive Disease after HD IL-2 in the Modern Era Suggesting Appropriate Drug Sequencing May Improve Outcomes CHICAGO, May 30, 2014 /PRNewswire/ -- Prometheus Laboratories Inc. announced today that analysis of data from the PROCLAIM(SM) national patient registry retrospective cohort shows improved overall survival in metastatic RCC patients treated with high-dose Proleukin(®) (aldesleukin) in the...

2011-03-01 08:00:00

SAN DIEGO, March 1, 2011 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today highlighted its financial results and product development progress for the year ended December 31, 2010. "Prometheus had another record year in 2010, our 14th consecutive year of sales growth," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "In addition, we made significant progress advancing a number of internal development programs,...

2010-10-11 12:14:00

SAN DIEGO, Oct. 11 /PRNewswire/ -- More than 120 cancer survivors and caregivers, cancer-treating physicians, and patient advocates gathered in San Diego to share their Proleukin® (aldesleukin for injection) treatment experiences. The theme of the meeting, Celebrating Our (Un)Common Journey Patient Summit, is believed to be the largest-ever gathering of metastatic renal cell carcinoma (kidney cancer) and metastatic melanoma (skin cancer) survivors. The Summit, which...

2010-06-02 07:00:00

SAN DIEGO, June 2 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced that it will report new data on its proprietary oncology diagnostic platform, a novel technology that forms the basis of the Company's recently announced collaboration with Bayer Schering Pharma AG. The new data will be highlighted in three separate presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago: Analysis of...

2010-01-26 06:00:00

SAN DIEGO, Jan. 26 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a commercialization agreement with Novartis under which Prometheus acquired exclusive rights to distribute, promote and sell PROLEUKIN® (aldesleukin) in the United States. Proleukin is a recombinant human interleukin-2 for treatment in adults with metastatic melanoma and metastatic kidney cancer. Net sales for Proleukin were...

2009-02-11 09:06:12

Providing a synthetic form of the immune system protein interleukin-2 (IL-2) to HIV-infected individuals already taking combination antiretroviral therapy boosts their numbers of CD4+ T cells, the key white blood cells destroyed by HIV, but fails to reduce their risk of HIV-associated opportunistic diseases or death compared with combination antiretroviral therapy alone.These are the findings of two large international clinical trials presented today at the Conference on Retroviruses and...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'